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The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral 
agents (DAAs) in HCV‑monoinfected and HIV/HCV‑coinfected patients. This was a prospective study 
of HCV‑monoinfected (n = 20), HIV/HCV‑co‑infected (n = 66) patients and healthy controls (n = 15). 
Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and 
serum concentrations of profibrotic transforming growth factor (TGF)‑β1 and CXC chemokine ligand 
4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) 
and 12 months after starting DAAs (M12). A M12 LS achievement of ≤ 9.5 kPa was considered the 
cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant 
differences were observed in LS decline between HCV‑ and HIV/HCV‑infected individuals. Changes 
of serum CXCL4, TGF‑β1 and HGF levels did not correlate with LS improvement. 16 out from 56 
patients (28%) with a baseline LS > 9.5 achieved a M12 LS ≤ 9.5. HCV‑monoinfected and HIV/HCV 
coinfected patients experienced a significant reduction of LS after sustained virological response. This 
improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of 
those with a baseline LS > 9.5 achieved a LS under this cutoff point.
The achievement of a sustained virological response (SVR) after treating chronic hepatitis C virus (HCV) infec-
tion reduces all-cause mortality and liver complications, such as cirrhosis, liver decompensation, and hepatocel-
lular  carcinoma1. The impact is even more relevant in human immunodeficiency virus (HIV)-coinfected patients, 
in which HCV-induced disease progresses more rapidly than in monoinfected  patients2.
It has been appreciated that inflammatory and coagulation pathways are both intrinsically involved in the 
pathophysiology of liver  damage3. Blood platelets are activated in inflammatory and immune processes and in 
the hemostatic disorders in the liver, releasing active compounds [such as transforming growth factor (TGF)-β1 
and CXC chemokine ligand 4 (CXCL4)]4. These proteins stimulate the fibrinogenesis and mitogenesis of Ito cells 
in the  liver5. Both TGF-β1 and CXCL4 are circulating biomarkers of tissue  fibrosis6,7.
Contradictory results have been published about serum concentrations of these markers. Some articles have 
demonstrated an increase of serum levels of TGF-β1 in HCV-monoinfected patients over time, mainly in patients 
with progressive liver  fibrosis8,9. However, other authors have observed that liver stiffness values are inversely 
correlated with TGF-β110, mainly in HIV/HCV coinfected  patients11,12. Anti-HCV therapy with interferon alpha 
and ribavirin affects the tissue expression of TGF-β1, and may thereby modulate hepatic fibrogenetic  events13.
In the case of CXCL4, serum levels are significantly increased in HCV‐infected patients with moderate to 
severe liver fibrosis compared to individuals with no or only mild fibrosis or to healthy  controls4,7. However, 
individuals with severe fibrosis and cirrhosis experience a decrease in CXCL4 serum levels owing to reduced 
numbers of  platelets4.
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In contrast with these profibrogenic molecules, hepatocyte growth factor (HGF) is a powerful inhibitor of 
hepatic stellate cells  activation14. In addition to a potential antifibrogenic effect, several studies have shown 
that HGF is involved in hepatic cell  regeneration15 and has a proangiogenic role in chronic viral liver  disease16. 
Another process wherein HGF has been involved is the development of hepatocellular carcinoma (HCC)17. Our 
group has demonstrated that high serum HGF levels are associated with greater liver fibrosis in HCV-infected 
 patients18. Serum HGF concentrations did not decrease after response to interferon plus  ribavirin19.
Serum-based fibrosis markers, like AST to platelets ratio index (APRI)20 and Fibrosis-4 (FIB-4)  score21, are 
readily available, but their diagnostic performance is suboptimal in both low- and high prevalence scenarios, 
with high false positive rates for detection of  cirrhosis22. Transient elastometry (TE) is a noninvasive procedure 
that assesses liver fibrosis by measuring liver stiffness (LS). LS measurement has shown a high accuracy for 
detecting liver fibrosis in HCV-infected patients, either  with21 or without HIV-coinfection22. TE has superior 
diagnostic performance in identifying cirrhosis, with lower rates of misclassification of  patients20. Several studies, 
carried out mostly among monoinfected individuals, have reported a significant decrease in liver stiffness after 
 treatment20,21. Nevertheless, there is scarce data regarding the impact of SVR on liver stiffness within HIV/HCV 
patients treated with  DAAs23–28. Furthermore, data about the relationship between modifications of liver fibrosis, 
both in HCV-monoinfected and HIV/HCV coinfected patients, and the serum concentrations of serum markers 
of fibrosis (CXCL4 or TGF-β1) or regeneration/proliferation (HGF), are also scarce and  controversial9,11,12, even 
though these parameters could be markers of fibrosis evolution.
Our objectives were: (1) analyze the liver stiffness improvement, measured by transient elastography, in 
patients with SVR after DAAs, and those factors related with it. (2) Compare the liver stiffnes evolution in HIV/
HCV coinfected and HCV-monoinfected patients. (3) Correlate changes of serum markers of fibrosis (CXCL4 
or TGF-β1) or proliferation (HGF), and modification of LS.
Results
Baseline results. A total of 86 patients naïve to DAA underwent HCV, achieving SVR, and had two TE and 
serum samples separated by 12 months. Baseline characteristics of the healthy controls, HCV-monoinfected and 
HIV/HCV coinfected patients are shown in Table 1.
Regarding HIV status, 100% had undetectable HIV viral load (< 50 copies/ml) and the median CD4 + count 
was 494/ml (312–791), with 9 subjects (14%) presenting severe immunosuppression (< 200 cells/ml).
CXCL4 and TGF-β1 were significantly decreased in HCV-monoinfected and HIV/HCV-coinfected patients 
in comparison with healthy controls. Serum levels of HGF were significantly increased in HIV/HCV coinfected 
patients compared with HCV-monoinfected or healthy individuals (Table 1).
Relationship between liver stiffness and other variables at baseline. LS was directly correlated 
with serum HGF (r = 0.600, p < 0.001) and inversely correlated with TGF-β1 levels (r = −0.374, p = 0.001), but not 
with CXCL4 concentration. TGF-β1 and CXCL4 levels were significantly correlated (r = 0.414, p < 0.001). Plate-
let counts were significantly correlated with serum CXCL4 (r = 0.400, p < 0.001) and TGF-β1 levels (r = 0.414, 
p < 0.001). In HIV/HCV coinfected patients, a significant correlation was detected between CD4 + T cell count 
and CXCL4 concentration (r = 0.309, p = 0.015), but not with TGF-β1 or HGF levels.
Modifications of liver stiffness and serum CXCL4, TGF‑β1 and HGF concentrations during fol‑
low‑up. Modifications from M0 to M12 in LS, APRI, FIB-4, CXCL4, TGF-β1 and HGF from M0 to M12 are 
shown in Table 2. A significant decrease of LS, APRI and FIB-4 values were detected from M0 to M12. Likewise, 
a significant diminution of HGF, but not of CXCL4 or TGF-β1, levels were observed. Changes of LS were not 
correlated with those of TGF-β1, CXCL4 or HGF levels (Fig. 1). Modifications of LS, APRI and FIB-4 score, 
CXCL4, TGF-β1 and HGF levels or CXCL4/platelets or TGF-β1/platelets ratios were similar in patients with and 
without cirrhosis (Fig. 2).
After the follow-up of 12 months, the median of LS decrease was 34% (IQR: − 59, 0). There was no significant 
difference in the percentage of LS, CXCL4, TGF-β1 and HGF levels decrease among HCV monoinfected and 
HIV/HCV coinfected patients (Fig. 3).
In HIV/HCV coinfected patients, there was no significant difference in LS change between individuals with 
a CD4 + T lymphocyte count higher or lower than 200/mm3 [− 37 (− 60, + 9) vs − 41 (− 78, + 3), respectively; 
p = 0.770]. Changes of serum TGF-β1, CXCL4 and HGF levels were similar in patients with more or less than 
200/mm3 (data not shown).
Modifications of fibrosis stage after SVR. Overall, 26% were reclassified into a different fibrosis stage 
after follow-up. No change in fibrosis stage was observed in patients with baseline non-significant fibrosis. In 
those with significant fibrosis (n = 41), 15 of them (37%) were re-classified as non-significant fibrosis and one 
(2%) as cirrhosis. In those with cirrhosis (n = 32), 7 of them (22%) were re-classified as significant fibrosis.
Because a LS ≤ 9.5 after DAAs is a cutoff indicative for discharge from specialized liver  clinic24, those patients 
with a baseline LS > 9.5 (n = 56) were evaluated 12 months after starting DAAs, grouped in function of the LS at 
M12 (Table 3). 16 of these patients achieved a LS ≤ 9.5 12 months after starting DAAs. After univariate analysis 
of variables from patients with a baseline LS > 9.5, parameters associated with a LS at M12 ≤ 9.5 were baseline LS, 
change in the LS after therapy, baseline platelets count and serum HGF levels; baseline TGF-β1 and APRI and 
risk factor for transmission “people who inject drugs” approached statistical significance. After binary logistic 
regression, only baseline LS was significantly associated with a M12 LS ≤ 9.5. Range of baseline LS of those with 
a M12 LS ≤ 9.5 after DAAs was 9.6–21.6, whereas that of patients with a M12 LS > 9.5 was 9.6–53.2.
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Table 1.  Baseline characteristics of the population of the cohort. HCV hepatitis C virus, HIV human 
immunodeficiency virus, IQR interquartile range, PWID people who inject drugs, AST aspartate amino-
transferase, ALT alanine amino-transferase, CXCL4 chemokine (C-X-C motif) ligand 4, TGF-β1 transforming 
growth factor β1, HGF hepatocyte growth factor, DAA directed antiviral (anti-HCV) agents.
Characteristic
Healthy controls 
(n = 15) (A)
HCV-infected patients p
Global (n = 86) (B)
HCV monoinfected 
patients (n = 20) (C)
HIV/HCV coinfected 
patients (n = 66) (D) A versus B A versus C A versus D C versus D
Male sex [n (%)] 10 (67) 63 (73) 8 (35) 58 (88) 0.831 0.222 0.103 < 0.001
Age (years), median 
(IQR) 55 (48–61) 55 (51–59) 60 (56–67) 54 (50–56) 0.230 0.195 0.299 < 0.001
PWID 35 (41) 1 (5) 34 (52) < 0.001
HCV genotype [n (%)] 0.001
1a 25 (28) 1 (5) 24 (36)
1b 28 (33) 14 (70) 14 (22)
2 0 (0) 0 (0) 0 (0)
3 12 (14) 3 (15) 9 (14)
4 18 (21) 1 (5) 17 (26)
Mixed 1a + 1b 3 (4) 1 (5) 2 (3)
Active and excessive 
alcohol consumption 
[n (%)]




31 (36) 4 (20) 27 (41) 0.114
HCV viral load (log 
UI/l), median (IQR) 6.0 (5.2–6.4) 5.6 (4.9–6.2) 6.1 (5.4 – 6.5) 0.046
AST (IU/l), median 
(IQR) 48 (30–71) 38 (29–62) 49 (31–74) 0.288
ALT (IU/l), median 
(IQR) 46 (33–82) 46 (27–91) 46 (34–80) 0.931
Baseline liver stiffness, 
median (IQR) 11.1 (8.8–20.1) 8.7 (4.7–11.5) 12.7 (9.3–26.3) 0.001
Baseline fibrosis stage 
[n (%)] 0.001
Non-significant fibrosis 
(F0–F1) 13 (15) 8 (40) 5 (8)
Significant fibrosis 
(F2–F3) 41 (48) 8 (40) 33 (50)
Cirrhosis (F4) 32 (37) 4 (20) 28 (42)
AST to Platelet Ratio 
Index (APRI), median 
(IQR)
0.95 (0.51–1.97) 0.46 (0.39–0.83) 1.11 (0.59–2.76) 0.002
Fibrosis-4 (FIB-4) 
score, median (IQR) 2.12 (1.54–4.74) 1.56 (1.29–2.00) 2.36 (1.71–5.63) 0.006
Prior liver decompen-
sation [n (%)] 4 (5) 0 (0) 4 (6) 1.000
Platelets/mm3  × 1000, 
median (IQR) 235 (210–262) 157 (102–212) 210 (183–247) 141 (92–186) < 0.001 0.178 < 0.001 < 0.001
Lymphocites/mm3, 
median (IQR) 2123 (1645–2514) 1908 (1404–2433) 2062 (1523–2261) 1890 (1388–2447) 0.257 0.865 0.212 0.871
CXCL4 (ng/ml), 
median (IQR) 6425 (4743–9599) 3002 (1435–5894) 2291 (1465–5079) 3174 (1435–6119) 0.002 0.003 0.003 0.649
TGF-β1 (pg/ml), 
median (IQR) 39,989 (35,356–57,606)
17,797 (11,502–
29,674) 20,958 (14,928–37,717) 15,968 (11,068–24,496) < 0.001  < 0.001  < 0.001 0.079
HGF (pg/ml), median 
(IQR) 2803 (2294–3111) 4549 (3043–6784) 2738 (1568–4564) 4833 (3488–8394)  < 0.001 0.987  < 0.001  < 0.001
DAA treatment regi-
mens [n (%)]  < 0.001
Sofosbuvir/ledipasvir 44 (51) 6 (30) 38 (58)
Sofosbuvir/simeprevir 2 (2) 0 (0) 2 (3)
Sofosbuvir/daclastasvir 9 (11) 0 (0) 9 (14)




21 (25) 7 (35) 14 (22)
Ombitasvir/pari-
taprevir/ritonavir 2 (2) 0 (0) 2 (3)
Elbasvir/grazoprevir 4 (5) 4 (20) 0 (0)
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Discussion
The prospective study presented here showed a significant decline on LS after 12 months with DAA therapy and 
achieving SVR. The LS improvement was not related with the existence of HIV/HCV coinfection or changes in 
serum levels of CXCL4, TGF-β1 or HGF.
Besides LS and APRI or FIB-4 score, serum levels of CXCL4, TGF-β1 and HGF were analyzed. It was remark-
able that a significant lower concentration of CXCL4 and TGF-β1 was observed in HCV-infected patients com-
pared with healthy controls. On the other hand, LS values were inversely correlated with TGF-β1 in our series, 
corroborating other authors  observations10–12. Lower concentrations of fibrosis markers could be explained by 
one or several of the following: (a) Serum concentrations could be a mirror image of liver levels, justifying the 
inverse correlation between TGF-β1 and LS. (b) Individuals with severe fibrosis and cirrhosis show decreased 
serum CXCL4 and TGF-β1 levels owing to reduced numbers of  platelets5. In fact, platelet counts were signifi-
cantly correlated with serum CXCL4 and TGF-β1 levels. (c) It could be also possible that the lower concentra-
tions of TGF-β1 and CXCL4 were related with a lower leukocyte or lymphocyte count. Effectively, in HIV/HCV 
coinfected patients, a significant correlation was detected between CD4 + T cell count (this was not a variable 
measured in HCV-monoinfected patients) and CXCL4 concentration.
HGF is a mitogenic cytokine implicated in regeneration of hepatic  tissue15. Because liver cirrhosis is character-
ized by hepatocyte necrosis, fibrosis and liver  regeneration3, the direct correlation among serum concentrations 
of HGF and LS, detected in this and in previous  articles18,29 was expected: circulating HGF level may reflect 
hepatic injury during feedback mechanism for repairing the hepatic tissue.
True fibrosis regression (biopsy-proven) is developed when SVR is  achieved30. Likewise, previous studies 
have indicated that LS measures may improve following anti-HCV antiviral  therapy31,32. This was also the case 
in our series: the median LS decrease after 12 months of follow-up was a 34%. Considering patients with sig-
nificant fibrosis, a 37% of them achieved posttreatment LS lower than 7.81 kPa (non-significant fibrosis), and 
a 22% of those with baseline cirrhosis achieved posttreatment LS lower than 15.56 kPa (significant fibrosis, but 
not cirrhosis).
Some studies have found that TE improvements could be overstated when compared with histologic 
 staging27,33, and that this decline might be correlated with inflammation or necrosis  improvement26,34–37. Our 
data support this hypothesis: if changes in LS were attributed only to fibrosis modifications, a direct correlation 
could have been detected with fibrosis marker changes; however, this correlation between changes in serum 
levels of CXCL4 or TGF-β1 and LS decline was not observed. Furthermore, changes in serum CXCL4 or TGF-β1 
concentrations from M0 to M12 were not significant. Attending to these results and measuring liver fibrosis by 
TE, we can conclude that CXCL4 or TGF-β1 measurements are not convenient for monitoring fibrosis changes.
The technical review on TE by the American Gastroenterological Association suggested that patients with-
out metabolic comorbidities, history of alcohol excess, or HBV–HIV coinfection, and with a liver stiffness 
of ≤ 9.5 kPa after sustained HCV viral response may be considered for discharge from a specialized liver  clinic24. 
A M12 LS ≤ 9.5 kPa was achieved by a 29% (16 out of 56) of those with baseline LS higher than this cutoff point. 
Baseline LS, change in the LS after therapy, baseline platelets count and serum HGF levels (but not CXCL4 or 
TGF-β1 concentration) were associated with the achievement of a M12 LS ≤ 9.5 kPa in the univariate analysis.
Baseline LS, but not baseline APRI or FIB-4, was able to discriminate between patients with an initial LS > 9.5 
who achieved a final LS lower than the mentioned cut-off point. In fact, only the baseline LS was independently 
associated with a M12 LS ≤ 9.5. However, patients with a wide range of baseline LS (9.6–21.6 kPa) could achieve 
that cutoff point, limiting the usefulness of baseline LS as predictive marker.
It has been stated that the achievement of SVR plays a determinant role in preventing additional liver 
 damage32. This is even more remarkable in HIV/HCV coinfected  patients33. Thus, a particular analysis of these 
patients was performed. They were characterized by a relatively preserved immune status, as proved by a median 
CD4 + count of 494/mm3, and undetectable HIV viral load. The LS and the proportion of them with liver cirrhosis 
was significantly higher than those of HCV-monoinfected patients. After 12 months of follow-up and having 
achieved SVR, HIV/HCV coinfected patients showed similar change of LS to HCV-monoinfected individuals. 
This decrease was similar in patients with more or less than 200 CD4 + lymphocytes/mm3, although the number 
of patients with less than 200/mm3 (n = 9) limits the extrapolation of results. Serum levels of profibrotic (TGF-
β1 and CXCL4) markers and changes of these serum concentrations were similar in HCV-monoinfected and 
HIV/HCV coinfected individuals, suggesting that liver fibrosis regulatory mechanisms function in a similar 
Table 2.  Modifications of liver stiffness, APRI, FIB-4 score and serum levels of CXCL4, TGF-β1 and 
HGF levels from baseline (M0) to 12 months after inclusion (M12). HCV hepatitis C virus, HIV human 
immunodeficiency virus, IQR interquartile range, DAA directed antiviral (anti-HCV) agents, CXCL4 
chemokine (C-X-C motif) ligand 4, TGF-β1 transforming growth factor β1, HGF hepatocyte growth factor.
Variable Baseline values (M0) Values after 12 months since inclusion (M12) p
Liver stiffness (kPa) 11.1 (8.8–20.1) 9.0 (5.8–18.6) 0.006
AST to platelet ratio Index (APRI), median (IQR) 0.95 (0.51–1.97) 0.37 (0.25–0.67) < 0.001
Fibrosis-4 (FIB-4) score, median (IQR) 2.12 (1.54–4.74) 1.75 (1.15–2.58) < 0.001
Serum CXCL4 concentration (ng/ml) 3002 (1435–5894) 2954 (1677–5121) 0.308
Serum TGF-β1 concentration (pg/ml) 17,797 (11,502–29,674) 16,412 (8628–36,031) 0.722
Serum HGF concentration (pg/ml) 4549 (3043–6784) 3803 (2533–5289) 0.001
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mode in both groups of patients. Attending to direct correlation among serum concentrations of HGF and LS, 
serum HGF were significantly increased in HIV/HCV coinfected patients, in which the proportion of cirrhotic 
Figure 1.  Bivariate correlation between changes in liver stiffness and serum concentrations of chemokine 
(C-X-C motif) ligand 4 (CXCL4) (A); transforming growth factor β1 (TGF-β1) (B), and hepatocyte growth 
factor (HGF) (C) concentrations in HCV-infected patients (n = 86), from inclusion (M0) to 12 months after 
that (M12). Patients started with direct HCV antiviral agents at inclusion and achieved sustained viral HCV 
response. Data are shown as percentage of change [100 × (M12 − M0)/M0].
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patients was higher. However, modification of serum HGF from M0 to M12 was similar in HCV-monoinfected 
and HIV/HCV coinfected individuals.
Our study might have some limitations. First, the sample size limited our ability to control for confounding 
factors that might interfere with SVR; the power of the study was insufficient to identify differences in several 
covariates, such as genotype, immune status or HCV viral load. Second, histologic assessment was not available, 
so correlations between TE results and biopsies could not be performed. Third, as it has been previously detected 
in articles that have compared HIV/HCV coinfected and HCV-monoinfected  patients38,39, HIV/HCV coinfected 
individuals are younger, with a predominance of drug use as risk factor. HCV genotype 1b predominantly affects 
to HCV-monoinfected individuals. However, these factors were not significantly correlated with serum levels 
of CXCL4, TGF-β1 and HGF or with LS measures or associated with an achievement of a LS < 9.5 kPa in the 
bivariate or multivariate analyses.
In summary, a third of HCV-infected patients that achieved HCV eradication experienced a significant reduc-
tion of LS, assessed by TE. LS decline was similar in HCV-monoinfected and HIV/HCV coinfected patients. The 
significance of this reduction is unclear, because there was no correlation with change in serum levels of fibrosis 
markers CXCL4 and TGF-β1 or in the proliferative HGF.
Methods
Patients and study design. This is a prospective cohort study of HCV-infected patients conducted at the 
Hospital Universitario Puerta del Mar (Cádiz, Spain). Two groups of patients were analyzed: HCV monoinfected 
patients (n = 20) and HIV/HCV coinfected patients (n = 66). A group of healthy individuals (n = 15) served as 
controls.
Subjects were eligible for analysis if they were treated with DAAs; started the therapy between 1 January 
2016 and 31 December 2018, and achieved sustained virological response. They underwent a baseline transient 
Figure 2.  Changes in liver stiffness (A), serum chemokine (C-X-C motif) ligand 4 (CXCL4) (B), transforming 
growth factor β1 (TGF-β1) (C), and hepatocyte growth factor (HGF) (D) concentrations in HCV-infected 
patients with (n = 32) or without (n = 54) liver cirrhosis, from inclusion to 12 months after that. Patients started 
with direct HCV antiviral agents at inclusion and achieved sustained viral HCV response. Data are shown as 
median, interquartile range and range.
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elastography (TE) and were taken a serum sample at inclusion and at least another TE and serum sample 
12 months after starting anti-HCV treatment.
All patients with detectable serum HCV RNA naïve to DAAs were consecutively enrolled. Anti-HCV therapy 
was performed under routine clinical care conditions, according to the best medical judgment and the prevailing 
HCV treatment guidelines at the time [www. seimc. org], based on HCV genotype, history of HCV treatment, drug 
interactions with antiretroviral treatment (ART) against HIV, and liver fibrosis assessed through TE. Anti-HCV 
therapy was administered for 12 weeks in all cases. In HIV/HCV coinfected patients, there were no modifications 
in the ART during the study period.
The exclusion criteria were hepatitis B virus coinfection, other concomitant causes of liver disease, including 
active alcohol abuse, active infections, and past or present treatment with steroids or immunosuppressive drugs 
prior to starting anti-HCV therapy.
The follow-up period covered from the date of the treatment onset (M0) until 12 months (M12) after starting 
anti-HCV treatment. Information on blood cells counts, kidney and liver function parameters, and virological 
markers was collected at M0, at week 12 posttreatment visits and at M12. Data about LS and fibrosis (CXCL4 
and TGF-β1)- or proliferation (HGF)-related variables was collected at M0 and M12.
Liver fibrosis staging. LS was examined through TE by the FibroScan system (Echosens, Paris, France) at 
M0 and M12. A minimum of 10 LS measurements were required. The median value was assumed to be repre-
sentative of LS. A set of measurements was considered to be reliable if the success rate was ≥ 60% and the inter-
quartile range was less than one-third of the median LS value. Unreliable measurements of LS were excluded. 
All measurements were obtained by two trained operators (MRP and JAGG) using a single device. Results, 
expressed in kilopascals (kPa), were categorized in three stages as follows: non-significant fibrosis (F0–F1), 
under 7.81 kPa; significant fibrosis (F2–F3), equal or more than 7.81 kPa; cirrhosis (F4), ≥ 15.56 kPa, according 
Figure 3.  Changes in liver stiffness (A), serum chemokine (C-X-C motif) ligand 4 (CXCL4) (B), transforming 
growth factor β1 (TGF-β1) (C), and hepatocyte growth factor (HGF) (D) concentrations in HCV-infected 
patients without (HCV + HIV−) (n = 20) or with (HCV + HIV +) (n = 66) HIV coinfection, from inclusion to 
12 months after that. Patients started with direct HCV antiviral agents at inclusion and achieved sustained viral 
HCV response. Data are shown as median, interquartile range and range.
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to Stebbing’s meta-analysis40. Besides fibrosis, other factors may also result in increased liver stiffness, such as the 
presence of severe hepatic inflammation, extrahepatic arteriovenous or biliary obstruction, and congestive heart 
 failure24. They were excluded by clinical and complementary explorations.
AST to platelets ratio index (APRI)20 and Fibrosis-4 (FIB-4)  score21 were also calculated.
Variables. Change in LS was the dependent variable and was defined by the difference between the values 
obtained at M12 and the M0 by TE, measured in kPa, divided by the M0 value [(M12 liver stiffness − M0 liver 
stiffness)/M0 liver stiffness].
Independent variables included: demographic factors [sex, age, HIV/HCV transmission mechanism, alco-
hol consumption (> 50 g/day, for more than 5 years)]; HIV-coinfection and HIV-related factors (viral load, 
CD4 + count and percentage); HCV-related factors (viral load, genotype, previous treatment experience); (d) 
other laboratory data (serum transaminases); (e) treatment-related factors (DAA regimen); (f) serum levels of 
fibrosis (CXCL4 and TGF-β1) and proliferation (HGF)-related markers; (g) APRI and FIB-4 score.
Changes from M0 to M12 of LS, APRI, FIB-4, or serum fibrosis and proliferation markers were calculated 
as the values at M12 minus the values at M0, divided by the values at M0 [(M12 value − M0 value)/M0 value].
SVR at week 12 (SVR12) was defined as HCV RNA undetectable at week 12 after the treatment had ended.
Table 3.  Differences of HCV-monoinfected and HIV/HCV coinfected patients with a baseline liver 
stiffness > 9.5 kPa in function of the achievement of a liver stiffness < 9.5 kPa, measured at 12 months after 
starting DAAs. HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, PWID 
people who inject drugs, DAA directed antiviral (anti-HCV) agents, APRI AST to Platelet Ratio Index, FIB-4 
Fibrosis-4 score, CXCL4 chemokine (C-X-C motif) ligand 4, TGF-β1 transforming growth factor β1, HGF 
hepatocyte growth factor.
Characteristic
Patients with M12 liver 
stiffness ≤ 9.5 kPa (n = 16)
Patients with M12 liver 
stiffness > 9.5 kPa (n = 40) p univariant Exp (B) (CI 95%) p multivariant
Male sex [n (%)] 11 (69) 34 (85) 0.263
Age (years), median (IQR) 54 (50–58) 55 (51–60) 0.473
PWID 4 (25) 22 (55) 0.074
HIV/HCV coinfection [n (%)] 5 (56) 35 (75) 0.259
HCV genotype [n (%)] 0.368
1a 6 (38) 12 (30)
1b 6 (38) 14 (35)
3 2 (12) 5 (13)
4 1 (6) 9 (23)
Mixed 1a + 1b 1 (6) 0 (0)
Excessive alcohol consumption [n (%)] 1 (6) 3 (7) 0.592
Treatment-experienced [n (%)] 16 (32) 8 (36) 0.789
Baseline HCV viral load (log UI/l), 
median (IQR) 6.3 (4.8–6.8) 5.9 (5.0–6.4) 0.384
Baseline fibrosis stage [n (%)] 0.003
Significant fibrosis (F2–F3) 12 (75) 12 (30)
Cirrhosis (F4) 4 (25) 28 (70)
Baseline liver stiffness, median (IQR) 11.6 (10.3–16.8) 20.1 (13.2–32.9) 0.002 0.887 (0.793–0.992) 0.036
Percentual change of liver stiffness after 
DAAs (%), median (IQR) − 46 (− 61, − 41) 5 (− 37, + 18)  < 0.001
Baseline APRI, median (IQR) 1.00 (0.42–2.06) 1.35 (0.71–2.97) 0.108
Percentual change of APRI after DAAs 
(%), median (IQR) − 44 (− 71, − 38) − 55 (− 65, − 30) 0.955
Baseline FIB-4, median (IQR) 1.76 (1.32–4.91) 3.33 (1.80–7.89) 0.054
Percentual change of FIB-4 after DAAs 
(%), median (IQR) − 7 (− 35, + 15) − 27 (− 44, 0) 0.257
Platelets/mm3 × 1000, median (IQR) 202 (137–232) 114 (78–169) 0.005
Baseline CXCL4 concentration (ng/ml), 
median (IQR) 3421 (2109–7199) 2239 (1284–5413) 0.381
Percentual change of CXCL4 levels after 
DAAs (%), median (IQR) 7 (− 25, + 75) 1 (− 46, + 89) 0.914
Baseline TGF-β1 concentration (pg/ml), 
median (IQR) 20,343 (8599–30,588) 11,778 (7855–22,045) 0.103
Percentual change of TGF-β1 levels 
after DAAs (%), median (IQR) − 2 (− 38, + 59) − 14 (− 32, + 74) 0.842
Baseline HGF concentration (pg/ml) 4324 (2960–5686) 6088 (3780–11,031) 0.019
Percentual change of HGF levels after 
DAAs (%), median (IQR) − 5 (− 39, + 8) − 20 (− 44, + 8) 0.677
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Statistical analysis. For comparisons of patient’s characteristics, we used the Fisher and Chi-square tests 
(categorical variables) or the Student’s t test and Mann–Whitney test (continuous variables), depending on the 
normality of distributions.
The primary outcome was the assessment of evolution of LS after 12 months of follow-up. Likewise, a LS equal 
or lower of 9.5 was selected, because a post-SVR LS of ≤ 9.5 kPa may be considered as a cutoff point for discharge 
from a dedicated liver  clinic24. To establish nonadjusted associations between LS decline and patient’s clinical 
or analytical findings, we used univariant models. Multivariable linear regression models were implemented to 
analyze the impact on LS of statistical significant independent variables. The study length was calculated from 
the date of the DAA regimen prescription to the 12 months after starting anti-HCV therapy. Statistical analyses 
were performed with SPSS for Windows version 22.0 (SPSS, Inc), considering a value of p < 0.05 significant.
Ethical aspects. The study was designed and conducted following the Helsinki declaration. The Ethics 
Committee of the Hospital Universitario Puerta del Mar (Cádiz) approved the study, and all the patients gave 
their written informed consent.
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